469 related articles for article (PubMed ID: 10752936)
1. The National Eye Institute Visual Function Questionnaire: experience of the ONTT. Optic Neuritis Treatment Trial.
Cole SR; Beck RW; Moke PS; Gal RL; Long DT
Invest Ophthalmol Vis Sci; 2000 Apr; 41(5):1017-21. PubMed ID: 10752936
[TBL] [Abstract][Full Text] [Related]
2. Reliability and validity of the National Eye Institute Visual Function Questionnaire-25 in patients with age-related macular degeneration.
Revicki DA; Rentz AM; Harnam N; Thomas VS; Lanzetta P
Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):712-7. PubMed ID: 19797233
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of minimum clinically meaningful changes in scores on the National Eye Institute Visual Function Questionnaire (NEI-VFQ) SST Report Number 19.
Submacular Surgery Trials Research Group
Ophthalmic Epidemiol; 2007; 14(4):205-15. PubMed ID: 17896299
[TBL] [Abstract][Full Text] [Related]
4. Utility of the National Eye Institute VFQ-25 questionnaire in a heterogeneous group of multiple sclerosis patients.
Noble J; Forooghian F; Sproule M; Westall C; O'Connor P
Am J Ophthalmol; 2006 Sep; 142(3):464-8. PubMed ID: 16935592
[TBL] [Abstract][Full Text] [Related]
5. Psychometric performance of the National Eye Institute visual function questionnaire in Latinos and non-Latinos.
Baker RS; Bazargan M; Calderón JL; Hays RD
Ophthalmology; 2006 Aug; 113(8):1363-71. PubMed ID: 16877075
[TBL] [Abstract][Full Text] [Related]
6. Baseline characteristics, the 25-Item National Eye Institute Visual Functioning Questionnaire, and their associations in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT).
Maguire M;
Ophthalmology; 2004 Jul; 111(7):1307-16. PubMed ID: 15234130
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the National Eye Institute visual function questionnaire in Graves' ophthalmopathy.
Bradley EA; Sloan JA; Novotny PJ; Garrity JA; Woog JJ; West SK
Ophthalmology; 2006 Aug; 113(8):1450-4. PubMed ID: 16769116
[TBL] [Abstract][Full Text] [Related]
8. Cross-validation of the Turkish version of the 25-item National Eye Institute Visual Functioning Questionnaire (NEI-VFQ 25).
Toprak AB; Eser E; Guler C; Baser FE; Mayali H
Ophthalmic Epidemiol; 2005 Aug; 12(4):259-69. PubMed ID: 16033747
[TBL] [Abstract][Full Text] [Related]
9. Validation and test characteristics of a 10-item neuro-ophthalmic supplement to the NEI-VFQ-25.
Raphael BA; Galetta KM; Jacobs DA; Markowitz CE; Liu GT; Nano-Schiavi ML; Galetta SL; Maguire MG; Mangione CM; Globe DR; Balcer LJ
Am J Ophthalmol; 2006 Dec; 142(6):1026-35. PubMed ID: 17046704
[TBL] [Abstract][Full Text] [Related]
10. Depression and the 25-item National Eye Institute Visual Function Questionnaire in older adults.
Owsley C; McGwin G
Ophthalmology; 2004 Dec; 111(12):2259-64. PubMed ID: 15582083
[TBL] [Abstract][Full Text] [Related]
11. Quality of life after macular translocation with 360 degrees peripheral retinectomy for age-related macular degeneration.
Cahill MT; Stinnett SS; Banks AD; Freedman SF; Toth CA
Ophthalmology; 2005 Jan; 112(1):144-51. PubMed ID: 15629835
[TBL] [Abstract][Full Text] [Related]
12. Effect of vitrectomy for epiretinal membrane on visual function and vision-related quality of life.
Okamoto F; Okamoto Y; Hiraoka T; Oshika T
Am J Ophthalmol; 2009 May; 147(5):869-74, 874.e1. PubMed ID: 19200531
[TBL] [Abstract][Full Text] [Related]
13. Health- and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials of submacular surgery: SST report no. 4.
Dong LM; Childs AL; Mangione CM; Bass EB; Bressler NM; Hawkins BS; Marsh MJ; Miskala P; Jaffee HA; McCaffrey LA;
Am J Ophthalmol; 2004 Jul; 138(1):91-108. PubMed ID: 15234287
[TBL] [Abstract][Full Text] [Related]
14. Is adjustment of National Eye Institute Visual Function Questionnaire scores for general health necessary in randomized trials?
Miskala PH; Bressler NM; Meinert CL
Am J Ophthalmol; 2004 May; 137(5):961-3. PubMed ID: 15126176
[TBL] [Abstract][Full Text] [Related]
15. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials.
Suñer IJ; Kokame GT; Yu E; Ward J; Dolan C; Bressler NM
Invest Ophthalmol Vis Sci; 2009 Aug; 50(8):3629-35. PubMed ID: 19255158
[TBL] [Abstract][Full Text] [Related]
16. Vision- and health-related quality of life in patients with visual field loss after postchiasmatic lesions.
Gall C; Lucklum J; Sabel BA; Franke GH
Invest Ophthalmol Vis Sci; 2009 Jun; 50(6):2765-76. PubMed ID: 19117930
[TBL] [Abstract][Full Text] [Related]
17. Validation of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) in age-related macular degeneration.
Orr P; Rentz AM; Margolis MK; Revicki DA; Dolan CM; Colman S; Fine JT; Bressler NM
Invest Ophthalmol Vis Sci; 2011 May; 52(6):3354-9. PubMed ID: 21282568
[TBL] [Abstract][Full Text] [Related]
18. Treatment and vision-related quality of life in the early manifest glaucoma trial.
Hyman LG; Komaroff E; Heijl A; Bengtsson B; Leske MC;
Ophthalmology; 2005 Sep; 112(9):1505-13. PubMed ID: 16019074
[TBL] [Abstract][Full Text] [Related]
19. Psychometric properties of the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25), Japanese version.
Suzukamo Y; Oshika T; Yuzawa M; Tokuda Y; Tomidokoro A; Oki K; Mangione CM; Green J; Fukuhara S
Health Qual Life Outcomes; 2005 Oct; 3():65. PubMed ID: 16248900
[TBL] [Abstract][Full Text] [Related]
20. Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: findings in patients with subfoveal choroidal neovascularization--SST Report No. 1.
Miskala PH; Hawkins BS; Mangione CM; Bass EB; Bressler NM; Dong LM; Marsh MJ; McCaffrey LD;
Arch Ophthalmol; 2003 Apr; 121(4):531-9. PubMed ID: 12695250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
